Invivyd (NASDAQ:IVVD) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Invivyd (NASDAQ:IVVD) in a research note released on Monday morning, MarketBeat.com reports. The firm issued an overweight rating and a $10.00 target price on the stock.

Several other equities research analysts have also issued reports on IVVD. Weiss Ratings reissued a “sell (d-)” rating on shares of Invivyd in a report on Saturday, September 27th. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Invivyd in a research note on Wednesday, August 27th. Finally, D. Boral Capital dropped their price target on shares of Invivyd from $3.00 to $1.00 and set a “buy” rating for the company in a research report on Monday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.14.

Invivyd Trading Up 22.4%

Shares of IVVD stock opened at $1.42 on Monday. Invivyd has a 12 month low of $0.35 and a 12 month high of $2.74. The company has a market capitalization of $170.60 million, a P/E ratio of -1.54 and a beta of 0.57. The stock has a 50 day moving average of $0.97 and a two-hundred day moving average of $0.80.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.08). The firm had revenue of $11.79 million for the quarter, compared to the consensus estimate of $23.16 million. Invivyd had a negative net margin of 238.33% and a negative return on equity of 177.89%. Sell-side analysts predict that Invivyd will post -1.64 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Jill Andersen sold 49,402 shares of Invivyd stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $0.57, for a total transaction of $28,159.14. Following the completion of the transaction, the insider directly owned 84,446 shares of the company’s stock, valued at $48,134.22. This trade represents a 36.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last ninety days, insiders have sold 277,654 shares of company stock worth $167,215. Company insiders own 25.40% of the company’s stock.

Institutional Trading of Invivyd

Hedge funds have recently modified their holdings of the company. AQR Capital Management LLC boosted its holdings in shares of Invivyd by 2,051.0% in the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock worth $249,000 after acquiring an additional 391,617 shares in the last quarter. Marshall Wace LLP bought a new position in Invivyd in the 2nd quarter valued at $158,000. Jane Street Group LLC acquired a new position in Invivyd in the second quarter worth $147,000. Two Sigma Investments LP boosted its stake in Invivyd by 125.3% in the fourth quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock worth $163,000 after purchasing an additional 204,188 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Invivyd during the first quarter worth $66,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.